SK Life Sciences’ XCOPRI (cenobamate tablets) Receives the US FDA’s Approval for Partial-Onset Seizures in Adults

 SK Life Sciences’ XCOPRI (cenobamate tablets) Receives the US FDA’s Approval for Partial-Onset Seizures in Adults

Shots:

  • The approval is based on two global studies (Study 013 and Study 017) assessing XCOPRI vs PBO and demonstrated significant reductions in seizure frequency vs PBO at all doses studied
  • Study 013 results: XCOPRI (200 mg/day) (56% vs 22%), zero seizures (28% vs 9%); Study 017: XCOPRI (100 mg/day). During maintenance phase of 013, 017 reduction in median seizures @ 100/200/400 mg/day (36%, 55%, 55% vs 24 %); (4%, 11%, 21% vs 1%)
  • XCOPRI (cenobamate tablets) is an anti-epileptic drug targeted for partial-onset seizures in adults with expected availability in the US in Q2’2020. Additionally, in 2019 SK biopharma signs an exclusive license agreement with Arvelle Therapeutics to develop and commercialize in EU

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post